Pharmaceuticals News and Research

RSS

State highlights: New La. abortion restrictions; new Mass. hospital deal; Medicare and ambulances in N.J.

A selection of health policy stories from Louisiana, Massachusetts, New Jersey, Wisconsin, Georgia, Missouri, Maryland, New York, Kansas and Washington state.

16 Jun 2014

Research roundup: Hospital readmissions; researchers mistrust social media; premiums in Washington state

Reducing hospital readmissions is a major target for current quality improvement and cost-containment efforts.

16 Jun 2014

Novel microscopy technology helps detect protein that plays key role in prostate cancer

Assemblies of proteins, known as protein complexes, have important functions in cells; protein complexes embedded in the cell membrane, for example, are responsible for the exchange with the extracellular environment.

16 Jun 2014

States, insurance plans wrestle over decisions to offer costly hepatitis C drug

The medication, named Sovaldi, has shown great promise in fighting the deadly disease, but it is very expensive: The treatment regimen runs about $84,000 per patient.

16 Jun 2014

First Edition: June 13, 2014

Today's headlines include various updates on what Virginia lawmakers did in an attempt to resolve the state's budget impasse and Medicaid expansion debate.

13 Jun 2014

BioAnalytix now fills critical gap in area of biologic drug development

Biologic drugs are highly complex, but they may be the answer to many medical illnesses and conditions that currently have no treatment available.

13 Jun 2014

Excessive abuse of alcohol causes structural damage at molecular level to the brain

Joint research between the University of the Basque Country (UPV/EHU) and the University of Nottingham has identified, for the first time, the structural damage caused at a molecular level to the brain by the chronic excessive abuse of alcohol.

13 Jun 2014

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Duloxetine Delayed-release Capsules.

12 Jun 2014

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.

12 Jun 2014

Aston University plans for new Medical School to train new generation of doctors

Aston University (UK) has announced plans for a new Medical School which will train a new generation of doctors in Birmingham and the West Midlands.

12 Jun 2014

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.

12 Jun 2014

Cogstate announces signing of first contract for Precision Recruitment tool

Cognition technology company Cogstate is pleased to announce the signing of its first contract for Precision Recruitment, a new web-based tool for streamlining patient recruitment for clinical drug trials.

12 Jun 2014

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has been granted Certificate of Good Manufacturing Practice (GMP) compliance for its cell therapy manufacturing facility in Besançon, France.

12 Jun 2014

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder.

11 Jun 2014

Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel).

11 Jun 2014

Healthcare Corporate Access Day to be held on June 24, 2014

ROTH Capital Partners, a full-service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Healthcare Corporate Access Day on Tuesday, June 24, 2014, at the Dorchester Hotel in London, U.K.

11 Jun 2014

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent claiming the composition of BL-7010, a novel polymer for the treatment of celiac patients.

11 Jun 2014

Protein Metrics introduces top-down analysis as part of 2.0 release of Byonic proteomics search engine

Protein Metrics, Inc., a leading provider of software for rapid and thorough protein and peptide characterization, today announced the introduction of top-down analysis as part of the 2.0 release of its Byonic™ proteomics search engine.

11 Jun 2014

RBCC's injectable technology poised to improve use of addiction treatment drug

Rainbow Coral Corp. received a boost recently when researchers reported that a medication that could help tens of thousands of alcoholics quit drinking are underused.

11 Jun 2014

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.

11 Jun 2014

Pharmaceuticals News and Research

State highlights: New La. abortion restrictions; new Mass. hospital deal; Medicare and ambulances in N.J.

Research roundup: Hospital readmissions; researchers mistrust social media; premiums in Washington state

Novel microscopy technology helps detect protein that plays key role in prostate cancer

States, insurance plans wrestle over decisions to offer costly hepatitis C drug

First Edition: June 13, 2014

BioAnalytix now fills critical gap in area of biologic drug development

Excessive abuse of alcohol causes structural damage at molecular level to the brain

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Aston University plans for new Medical School to train new generation of doctors

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Cogstate announces signing of first contract for Precision Recruitment tool

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Auxilium and Prasco introduce authorized generic version of Testim

Healthcare Corporate Access Day to be held on June 24, 2014

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

Protein Metrics introduces top-down analysis as part of 2.0 release of Byonic proteomics search engine

RBCC's injectable technology poised to improve use of addiction treatment drug

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence